Edgestream Partners L.P. Purchases 66,293 Shares of Boston Scientific Corporation $BSX

Edgestream Partners L.P. lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 340.7% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 85,752 shares of the medical equipment provider’s stock after buying an additional 66,293 shares during the quarter. Edgestream Partners L.P.’s holdings in Boston Scientific were worth $5,381,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new stake in Boston Scientific in the 4th quarter worth $2,199,395,000. Assenagon Asset Management S.A. lifted its position in shares of Boston Scientific by 133.6% in the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock valued at $631,135,000 after acquiring an additional 5,751,760 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Boston Scientific by 31.0% in the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after acquiring an additional 3,907,981 shares during the period. Maverick Capital Ltd. purchased a new stake in shares of Boston Scientific during the fourth quarter worth about $280,735,000. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Boston Scientific by 25.9% during the first quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after purchasing an additional 2,856,040 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted earnings of $0.86 per share and revenue of $5.44 billion, exceeding consensus estimates of $0.83 and $5.38 billion, respectively. Revenue increased 7.5% year over year, while management highlighted approximately 7% organic sales growth and a 15% increase in adjusted EPS. Boston Scientific Q2 earnings call highlights
• Positive Sentiment: Management’s multiyear restructuring plan is intended to improve efficiency and generate roughly $500 million in savings, supporting longer-term margins despite restructuring costs of up to $800 million. Reported workforce reductions are expected to affect operations in Ireland and Costa Rica. Boston Scientific restructuring cuts
• Positive Sentiment: Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year over year, with thrombectomy revenue rising 12.5% and embolization and access revenue increasing 20.0%. The results provide supportive operating momentum for Boston Scientific’s pending acquisition of Penumbra, although PEN will not issue full-year guidance during the transaction. Penumbra second-quarter financial results
• Neutral Sentiment: Analyst sentiment remains broadly constructive but more cautious: UBS reaffirmed a Buy rating with a $74 target, while TD Cowen and Truist maintained Buy ratings despite lowering targets to $56 and $57. Argus reiterated a Hold rating, and BTIG reduced its expectations.
• Negative Sentiment: Boston Scientific lowered its full-year outlook because of headwinds affecting its electrophysiology and WATCHMAN portfolios. Analysts also cited a reset in expectations for these businesses, limiting the near-term upside from the earnings beat. Boston Scientific lowered full-year guidance
• Negative Sentiment: A recall involving the Rapid Refill Continuous Injection System adds a product and execution risk, while the restructuring will create near-term charges before expected savings are realized. Boston Scientific earnings, recall and restructuring

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Royal Bank Of Canada lowered their price target on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday. Piper Sandler reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Truist Financial reduced their price objective on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday. The Goldman Sachs Group set a $71.00 target price on shares of Boston Scientific in a research report on Thursday, May 28th. Finally, Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Trading Up 1.6%

BSX opened at $46.75 on Friday. The firm has a market cap of $69.48 billion, a P/E ratio of 18.93, a P/E/G ratio of 0.94 and a beta of 0.58. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The stock has a 50-day moving average of $46.13 and a 200 day moving average of $62.26.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the previous year, the firm posted $0.75 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has initiated a stock buyback program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.

Insider Activity

In related news, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have purchased 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.